Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma Journal Article


Authors: von Tresckow, B.; Fanale, M.; Ardeshna, K. M.; Chen, R.; Meissner, J.; Morschhauser, F.; Moskowitz, C.; Zinzani, P. L.; Giezek, H.; Balakumaran, A.; Vo, T. T.; Raut, M.; Brice, P.
Article Title: Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma
Abstract: In KEYNOTE-087, pembrolizumab had a 69% overall response rate and acceptable safety in patients with relapsed/refractory classical Hodgkin lymphoma (rrHL). We assessed health-related quality of life (HRQoL) in KEYNOTE-087. The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (QLQ-C30) and the EuroQoL Five Dimensions Questionnaire 3-level version (EQ-5D) were administered to 206 patients across three cohorts defined by lymphoma progression after: (1) autologous stem cell transplantation (ASCT) and subsequent brentuximab vedotin (BV) (n = 69); (2) salvage chemotherapy and BV (n = 79); and (3) ASCT without post-transplantation BV (n = 58). Compliance/completion rates were ≥90% at week 12 and ≥70% at week 24. QLQ-C30 global health status/QoL and EQ-5D visual analog scale scores showed mean increases from baseline in overall health at all assessed timepoints. With few exceptions, mean improvements from baseline to weeks 12 and 24 in QLQ-C30 functional and symptom scores occurred in all cohorts. Clinicaltrials.gov identifier: NCT02453594. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: adult; cancer chemotherapy; aged; major clinical study; chemotherapy; prospective study; quality of life; phase 2 clinical trial; cohort analysis; autologous stem cell transplantation; multicenter study; patient compliance; patient-reported outcomes; longitudinal study; classical hodgkin lymphoma; global health; patient-reported outcome; medication compliance; brentuximab vedotin; health-related quality-of-life; human; priority journal; article; pembrolizumab; european organization for research and treatment of cancer quality of life questionnaire core 30; european quality of life 5 dimensions questionnaire; keynote-087; european quality of life 5 dimensions visual analogue scale
Journal Title: Leukemia and Lymphoma
Volume: 60
Issue: 11
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2019-01-01
Start Page: 2705
End Page: 2711
Language: English
DOI: 10.1080/10428194.2019.1602262
PUBMED: 31012356
PROVIDER: scopus
DOI/URL:
Notes: Article -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Craig Moskowitz
    407 Moskowitz